BLOOD RESEARCH VOLUME 48ㆍNUMBER 2

First Page		Document Content
Triazines Orphan drugs Myeloid leukemia Azacitidine lactams Myelodysplastic syndrome Decitabine International Prognostic Scoring System Lenalidomide Medicine Oncology Nucleosides		BLOOD RESEARCH VOLUME 48ㆍNUMBER 2 Add to Reading List Source URL: www.ncbi.nlm.nih.gov Download Document from Source Website File Size: 502,30 KB Share Document on Facebook

	Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma DocID: 15uOM - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION DocID: 13My6 - View Document
	June 14, 2013 Astex Pharmaceuticals Announces Presentation of Updated Results of SGI[removed]Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology As DocID: 11odm - View Document
	Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA) DocID: 10gfI - View Document
	DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML DocID: Z1WQ - View Document